Skip to main content

Anand Bhaskar's Form 4 filing

Reata Pharmaceuticals IncRETA · filed May 17, 2023

Accession no.
0001209191-23-030181
Filed
May 17, 2023
Trade date
May 15-16, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $92.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Anand BhaskarCIK 0001890784Officer (SVP, Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 15, 2023Class A common stockSSaleDisposed−950$85.98F2−$81,68125,815Direct
May 16, 2023Class A common stockSSaleDisposed−136$81.10−$11,029.625,679Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $85.92 to $86.00 The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)